Ōsaka, Japan
Ōsaka, Japan

Time filter

Source Type

Patent
Sawai Pharmaceutical Co. | Date: 2015-06-02

A candesartan cilexetil-containing preparation contains candesartan cilexetil and lauromacrogol. The lauromacrogol may be contained at a ratio of 2.4 parts by weight or less with respect to 100 parts by weight of the candesartan cilexetil-containing preparation. The candesartan cilexetil-containing preparation may further contain at least one kind of pharmacologically acceptable additives among a diluent, a disintegrant and a binder.


Patent
Sawai Pharmaceutical Co. | Date: 2014-02-19

The present invention provides: a pitavastatin-containing preparation, which is characterized by containing pitavastatin or a pharmacologically acceptable salt thereof and at least one basic additive selected from the group consisting of basic magnesium compounds and basic calcium compounds, and which is also characterized in that an aqueous solution or aqueous dispersion thereof has a pH of more than 8 but 10 or less; and a method for producing a pitavastatin-containing preparation, which is characterized in that the above-described specific basic additive is blended with pitavastatin or a pharmacologically acceptable salt thereof so that an aqueous solution or aqueous dispersion thereof has a pH of more than 8 but 10 or less.


Patent
Sawai Pharmaceutical Co. | Date: 2015-12-07

Provided is a method for measuring endotoxin in which glucose-1-phosphate or glucose-6-phosphate is added to a sample and a detection reagent is added to the sample. Furthermore, a reagent for measurement according to the present invention contains glucose-1-phosphate or glucose-6-phosphate. The glucose-1-phosphate or the glucose-6-phosphate may be added in the form of a solution to the sample. The sample may be a pharmaceutical, and a solution containing the glucose-1-phosphate or the glucose-6-phosphate may be prepared so as to have a concentration of the glucose-1-phosphate or the glucose-6-phosphate of 1 mM or more and 25 mM or less.


Patent
Sawai Pharmaceutical Co. | Date: 2016-12-21

Provided is an orally disintegrating tablet coated with a film, in which the time required for dissolving the film is short, and which has good feeling upon ingestion and can be produced readily in a large quantity. The orally disintegrating tablet according to the present invention is coated with a composition for film coating purposes, wherein the composition comprises a water-soluble and ethanol-insoluble coating film base material and at least one plasticizer selected from the group consisting of propylene glycol and polyethylene glycol that has a liquid or semisolid form at room temperature. Alternatively, the orally disintegrating tablet according to the present invention is coated with a composition for film coating purposes, wherein the composition comprises a water-soluble and ethanol-insoluble coating film base material and at least one plasticizer selected from the group consisting of propylene glycol and polyethylene glycol that has a liquid or semisolid form at room temperature, and wherein the amount of the plasticizer contained is larger by 10% by weight or more than the amount of the coating film base material.


Patent
Sawai Pharmaceutical Co. | Date: 2015-07-31

Provided is a stable multilayer tablet containing telmisartan and hydrochlorothiazide, in which the decomposition of hydrochlorothiazide during storage, etc., is suppressed. A multilayer tablet comprising a first layer containing telmisartan, meglumine, and a moisture-absorbing substance and a second layer containing hydrochlorothiazide is provided. The moisture-absorbing substance may be a porous moisture-absorbing substance. The porous moisture-absorbing substance may be selected from light anhydrous silicic acid, synthetic aluminum silicate, natural aluminum silicate, calcium silicate, magnesium silicate, magnesium aluminosilicate, magnesium aluminometasilicate, hydrated silicon dioxide, and silicon dioxide.


Patent
Sawai Pharmaceutical Co. | Date: 2015-07-30

The present invention provides a pharmaceutical composition containing candesartan cilexetil, which is produced by wet granulation using a dispersion liquid of candesartan cilexetil together with a powdery additive. The dispersion liquid may also contain a water-soluble polymer, a sugar alcohol, or a stabilizer, and the water-soluble polymer may be hydroxypropylcellulose. The sugar alcohol may be mannitol. In addition, the stabilizer may be lauromacrogol.


Patent
Sawai Pharmaceutical Co. | Date: 2015-12-09

The present invention provides a pharmaceutical composition containing candesartan cilexetil, which is produced by wet granulation using a dispersion liquid of candesartan cilexetil together with a powdery additive. The dispersion liquid may also contain a water-soluble polymer, a sugar alcohol, or a stabilizer, and the water-soluble polymer may be hydroxypropylcellulose. The sugar alcohol may be mannitol. In addition, the stabilizer may be lauromacrogol.


A production method of pharmaceutical composition contains candesartan cilexetil, comprising dissolving a water-soluble polymer and a sugar alcohol to purified water and dispersing candesartan cilexetil to prepare a dispersion liquid of candesartan cilexetil, granulating by a wet process using the dispersion liquid together with a powdery additive to obtain a granulated product, drying the granulated product, particle size regulating the granulated product; and tableting the granulated product, wherein the dispersion liquid contains the amount of water-soluble polymer within a range of 0.05 parts by weight or more and 0.5 parts by weight or less, based on 100 parts by weight of the pharmaceutical composition, and the dispersion liquid contains the amount of sugar alcohol within a range of 5 parts by weight or more and 20 parts by weight or less, based on 100 parts by weight of the pharmaceutical composition.


Patent
Sawai Pharmaceutical Co. | Date: 2016-08-10

Provided is an orally disintegrating tablet coated with film that allows the time elapsed before a film thereof dissolves to be shorter, has a good feel when the tablet is taken, and is capable of being easily mass-produced. The orally disintegrating tablet coated with film is coated with a film coating composition, the film coating composition comprises a water-soluble and ethanol-insoluble film coating base; and at least one plasticizer selected from the group consisting of propylene glycol and polyethylene glycol in a liquid or semisolid state at room temperature. The orally disintegrating tablet coated with film is coated with a film coating composition, the film coating composition comprises a water-soluble and ethanol-insoluble film coating base; and at least one plasticizer selected from the group consisting of propylene glycol and polyethylene glycol in a liquid or semisolid state at room temperature, and contains the plasticizer in 10% by weight or more with respect to a weight of the film coating base.


Patent
Sawai Pharmaceutical Co. | Date: 2015-12-09

Provided is a stable multilayer tablet containing telmisartan and hydrochlorothiazide, in which the decomposition of hydrochlorothiazide during storage, etc., is suppressed. A multilayer tablet comprising a first layer containing telmisartan, meglumine, and a moisture-absorbing substance and a second layer containing hydrochlorothiazide is provided. The moisture-absorbing substance may be a porous moisture-absorbing substance. The porous moisture-absorbing substance may be selected from light anhydrous silicic acid, synthetic aluminum silicate, natural aluminum silicate, calcium silicate, magnesium silicate, magnesium aluminosilicate, magnesium aluminometasilicate, hydrated silicon dioxide, and silicon dioxide.

Loading Sawai Pharmaceutical Co. collaborators
Loading Sawai Pharmaceutical Co. collaborators